PKG Inc.’s CEO Excited With the Potential Acquisition by Cerebain Biotech

Cerebain Biotech Corp. (OTC: CBBT), (the “Company” or “Cerebain”) previously announced, on August 25, 2020, that it had entered into a Letter of Intent to purchase the assets of PKG, Inc. (PKG).

Almir Garibovic, CEO of PKG Inc., stated “After 30 years in business, PKG, Inc. is thrilled that we have entered into a letter of intent to be acquired by Cerebain Biotech Corp. We are excited by this partnership because of our complementary strengths and it will enable us to fulfill our vision and values, while we continue to provide our customers with innovative design, technologies and manufacturing capabilities as never before.”

Eric Clemons, CEO of Cerebain, added “We are committed to evaluating both Companies strategic core competencies to enhance value for our shareholders while maintaining our focus on the continued development of Cerebain’s device for the treatment of Alzheimer’s Disease as well as aggressively managing PKG’s current operations.”

Forward Looking Statements

This news release contains certain “forward- looking statements.” Forward-looking statements are based on current expectations and assumptions and are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified, and many of which are beyond the Company’s control. The forward-looking statements are also identified through the use of words “believe,” enable,” “may,” “will,” “could,” “intends,” “estimate,” “anticipate,” “plan,” “predict” “probable,” “potential,” “possible,” “should,” “continue,” and other words of similar meaning. Actual results could differ materially from these forward-looking statements as a result of a number of risk factors detailed in the Company’s reports filed with OTC Markets. Given these risks and uncertainties, investors are cautioned not to place undue reliance on such forward-looking statements and no assurances can be given that such statements will be achieved.